contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


gubra-further-validation-of-the-streamline-platform-adding-further-long-term-optionality

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Equity Research Analyst

Philip Coombes

Gubra is a pharmaceutical company. The company's operations are focused on the early stages of drug development. They primarily conduct research and development in the area of metabolic and fibrotic diseases. The company's product portfolio includes several brands and drugs, and the operations are conducted on a global level, with the largest presence in North America and the Nordic region. The headquarters are located in Hørsholm, Denmark.

Gubra

Amylyx Pharmaceuticals has selected AMX0318, a long-acting drug discovered with Gubra, as a development candidate, triggering a USD 4m milestone and carrying >USD 50m in potential milestones plus royalties. While modest versus Gubra’s AbbVie partnership and UCN2, the progression further validates the streaMLine platform and its long-term optionality.


This afternoon Gubra announced that its partner Amylyx Pharmaceuticals is has selected its AMX0318 asset, a long-acting GLP-1 receptor antagonist, discovered in collaboration with Gubra, as a formal development candidate for post-bariatric hypoglycemia and other rare diseases.
The candidate met all key selection criteria, including strong chemical stability, in-vitro potency, in-vivo efficacy and tolerability, and a pharmacokinetic profile consistent with long-acting dosing. This means that IND-enabling studies can be initiated. IND submission is targeted for 2027, pending submission of successful completion of IND-enabling studies.
As part of the nomination, Gubra will receive a USD 4m milestone, with the collaboration carrying &gt;USD 50m in total potential milestones plus mid-single-digit royalties on future sales. From an investment perspective, the news provides further third-party validation of Gubra&#x2019;s AI-driven streaMLine platform and its ability to generate differentiated, high-quality peptide drug candidates that meet big-pharma and biotech development standards across indications.&#xa0;
While the economics are modest relative to Gubra&#x2019;s headline partnerships and the programme remains early-stage, repeated external progression of streaMLine-derived assets reinforces platform credibility and long-term optionality. That said, the main value drivers for Gubra remain the AbbVie partnership around ABBV-295 and the internally owned UCN2 obesity programme, which continue to dominate our valuation and near- to mid-term investment case.
Learn more about Gubra&apos;s pipeline, and dual Discorvery &amp; Partnerships (D&amp;P) and CRO business model, and some valuation perspectives around Gubra&apos;s signature assets in the latest HCA one-pager here:&#xa0;<a href="https://www.inderes.dk/research/gubra-one-pager-strong-differentiated-obesity-pipeline-and-valuation-update">https://www.inderes.dk/research/gubra-one-pager-strong-differentiated-obesity-pipeline-and-valuation-update</a> Disclaimer: HC Andersen Capital receives payment from Gubra for a DigitalIR/Corporate Visibility agreement. / Philip Coombes 14:26 08/01/2026, updated 10:52 09/01/2026&#xa0;
&#xa0;

HC Andersen Capital

Gubra - Further validation of the streaMline platform, adding further long-term optionality